Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma

A randomized phase III trial

Takuji Okusaka, Hiroshi Kasugai, Yasukazu Shioyama, Katsuaki Tanaka, Masatoshi Kudo, Hiromitsu Saisho, Yukio Osaki, Michio Sata, Shigetoshi Fujiyama, Takashi Kumada, Keiko Sato, Seiichiro Yamamoto, Shiro Hinotsu, Tosiya Sato

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC.

Original languageEnglish
Pages (from-to)1030-1036
Number of pages7
JournalJournal of Hepatology
Volume51
Issue number6
DOIs
Publication statusPublished - Dec 2009
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Drug Therapy
Survival
Porifera
Gelatin
Hepatic Artery
Tomography
Liver
Therapeutics
Growth
Neoplasms

Keywords

  • Gelatin sponge
  • Lipiodol emulsion
  • Overall survival
  • Survival benefit
  • Zinostatin stimalamer

ASJC Scopus subject areas

  • Hepatology

Cite this

Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma : A randomized phase III trial. / Okusaka, Takuji; Kasugai, Hiroshi; Shioyama, Yasukazu; Tanaka, Katsuaki; Kudo, Masatoshi; Saisho, Hiromitsu; Osaki, Yukio; Sata, Michio; Fujiyama, Shigetoshi; Kumada, Takashi; Sato, Keiko; Yamamoto, Seiichiro; Hinotsu, Shiro; Sato, Tosiya.

In: Journal of Hepatology, Vol. 51, No. 6, 12.2009, p. 1030-1036.

Research output: Contribution to journalArticle

Okusaka, T, Kasugai, H, Shioyama, Y, Tanaka, K, Kudo, M, Saisho, H, Osaki, Y, Sata, M, Fujiyama, S, Kumada, T, Sato, K, Yamamoto, S, Hinotsu, S & Sato, T 2009, 'Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial', Journal of Hepatology, vol. 51, no. 6, pp. 1030-1036. https://doi.org/10.1016/j.jhep.2009.09.004
Okusaka, Takuji ; Kasugai, Hiroshi ; Shioyama, Yasukazu ; Tanaka, Katsuaki ; Kudo, Masatoshi ; Saisho, Hiromitsu ; Osaki, Yukio ; Sata, Michio ; Fujiyama, Shigetoshi ; Kumada, Takashi ; Sato, Keiko ; Yamamoto, Seiichiro ; Hinotsu, Shiro ; Sato, Tosiya. / Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma : A randomized phase III trial. In: Journal of Hepatology. 2009 ; Vol. 51, No. 6. pp. 1030-1036.
@article{02ae630f31364b578cd7d4850522fdf5,
title = "Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: A randomized phase III trial",
abstract = "Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC.",
keywords = "Gelatin sponge, Lipiodol emulsion, Overall survival, Survival benefit, Zinostatin stimalamer",
author = "Takuji Okusaka and Hiroshi Kasugai and Yasukazu Shioyama and Katsuaki Tanaka and Masatoshi Kudo and Hiromitsu Saisho and Yukio Osaki and Michio Sata and Shigetoshi Fujiyama and Takashi Kumada and Keiko Sato and Seiichiro Yamamoto and Shiro Hinotsu and Tosiya Sato",
year = "2009",
month = "12",
doi = "10.1016/j.jhep.2009.09.004",
language = "English",
volume = "51",
pages = "1030--1036",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma

T2 - A randomized phase III trial

AU - Okusaka, Takuji

AU - Kasugai, Hiroshi

AU - Shioyama, Yasukazu

AU - Tanaka, Katsuaki

AU - Kudo, Masatoshi

AU - Saisho, Hiromitsu

AU - Osaki, Yukio

AU - Sata, Michio

AU - Fujiyama, Shigetoshi

AU - Kumada, Takashi

AU - Sato, Keiko

AU - Yamamoto, Seiichiro

AU - Hinotsu, Shiro

AU - Sato, Tosiya

PY - 2009/12

Y1 - 2009/12

N2 - Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC.

AB - Background/Aims: Transcatheter arterial chemoembolization (TACE) is a combination of transarterial infusion chemotherapy (TAI) and embolization, and has been widely used to treat patients with hepatocellular carcinoma (HCC). However, since the impact of adding embolization on the survival of patients treated with TAI had never been evaluated in a phase III study, we conducted a multi-center, open-label trial comparing TACE and TAI to assess the effect of adding embolization on survival. Methods: Patients with newly diagnosed unresectable HCC were randomly assigned to either a TACE group or a TAI group. Zinostatin stimalamer was injected into the hepatic artery, together with gelatin sponge in the TACE group and without gelatin sponge in the TAI group. Treatment was repeated when follow-up computed tomography showed the appearance of new lesions in the liver or re-growth of previously treated tumors. Results: Seventy-nine patients were assigned to the TACE group, and 82 were assigned to the TAI group. The two groups were comparable with respect to their baseline characteristics. At the time of the analysis, 51 patients in the TACE group and 58 in the TAI group had died. The median overall survival time was 646 days in the TACE group and 679 days in the TAI group (p = 0.383). Conclusions: The results of this study suggest that treatment intensification by adding embolization did not increase survival over TAI with zinostatin stimalamer alone in patients with HCC.

KW - Gelatin sponge

KW - Lipiodol emulsion

KW - Overall survival

KW - Survival benefit

KW - Zinostatin stimalamer

UR - http://www.scopus.com/inward/record.url?scp=71849107086&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849107086&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2009.09.004

DO - 10.1016/j.jhep.2009.09.004

M3 - Article

VL - 51

SP - 1030

EP - 1036

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 6

ER -